
A recent clinical trial unveiled the potential of Simnotrelvir, a selective 3C-like protease inhibitor, in combating COVID-19. Administered alone or with ritonavir, it showed promising safety and tolerability, with a low accumulation index. The recommended dosage of 750 mg/100 mg Simnotrelvir/Ritonavir twice daily demonstrated ample concentrations to inhibit 90% of SARS-CoV-2 in vitro, even under fasted conditions. These findings support its future development as a crucial antiviral in the fight against the pandemic.
Like
Save
Share